OakChart

Apollomics Inc

APLMHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

18.12-0.48 (-2.58%)
2026-11-12 00:15 CET
Market cap
54.22 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-7.22 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.26
P/E
-
Compare

Price

APLM against its 20, 50 and 200-day averages
2050200
15.0020.0025.00210K419KVolumeApr 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26APLMclose 18.1220-day 20.3250-day 22.78200-day 18.9518.1252w high

35.9% under the 52-week high of 28.29 on 3 Sep 2026. 52-week low 10.01 on 30 Oct 2025. Last 15 sessions, 37.8% high to low

Volume 0.05× normal · the line is the 50-bar volume average

Profile

APLM
52-week range, 35% of the way up
12.5828.29

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in May 2015 and is headquartered in Foster City, CA.

Employees14
IPONov 26, 2021
Beta1.58
ATR, 14d1.60
Rel volume0.05
Short float0.44%
Insider own57.41%
Inst own0.37%

Snapshot

6 groups

Valuation

Index-
Market Cap52.82M
Enterprise Value-
Income-7.22M
Sales0.00M
Book/sh-
Cash/sh0.35
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees14
IPONov 26, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C52.30
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio-
Current Ratio0.15
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.26
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y50.29% 18.23%
Sales past 3/5Y- -
EPS Y/Y TTM99.08%
Sales Y/Y TTM-100.00%
EPS Q/Q-1224.24%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own57.41%
Insider Trans53.51%
Inst Own0.37%
Inst Trans91.99%
ROA-108.32%
ROE-1305.37%
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-10.81%
SMA50-20.45%
SMA200-4.36%
Trades-

Technical

Shs Outstand2.92M
Shs Float1.24M
Short Float0.44%
Short Ratio0.41
Short Interest0.01M
52W High28.29 -35.95%
52W Low12.58 44.04%
Volatility9.86% 6.85%
ATR (14)1.60
RSI (14)38.23
Beta1.58
Rel Volume0.05
Avg Volume13.30K
Volume692

Performance

Perf Week-4.63%
Perf Month-15.01%
Perf Quarter4.32%
Perf Half Y33.95%
Perf YTD-3.08%
Perf Year18.35%
Perf 3Y-77.88%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price50.00
Prev Close18.60
Price18.12
Change %-2.58%

Peers

Mkt cap
TickerCompanyMkt cap
AAPGAscentage Pharma Group International ADR1.40B
ANLAdlai Nortye Group Ltd ADR637.22M
BLSMBlossomHill Therapeutics Inc512.38M
ONCBeOne Medicines Ltd ADR44.22B
AVBPArriVent BioPharma Inc698.52M
ELVNEnliven Therapeutics Inc3.77B
KZIAKazia Therapeutics Limited ADR84.92M
TYRATyra Biosciences Inc1.44B
NBPNovaBridge Biosciences ADR99.88M
BYSIBeyondSpring Inc26.48M

Insider trading

latest 14 of 19
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
LIN PETER KUAN-HOWChief Financial OfficerSep 15 '26Option Exercise0.0010,000058,979Sep 17 08:55 PM
CHEN HONG-JUNGDirectorSep 15 '26Option Exercise0.0050004,120Sep 17 08:49 PM
Chen Yi-KueiChief Operating OfficerSep 15 '26Option Exercise0.005,000020,100Sep 17 08:48 PM
TSAI HSIEN-SHUDirectorSep 15 '26Option Exercise0.0050002,000Sep 17 08:47 PM
Yen Hung HsienDirectorSep 15 '26Option Exercise0.005000500Sep 17 08:44 PM
Chen Hung-WenChief Executive OfficerSep 15 '26Option Exercise0.005,0000423,334Sep 17 08:38 PM
Huang Ya-ChiDirectorAug 17 '26Option Exercise0.0050001,500Aug 24 08:51 PM
Chen Yi-KueiChief Operating OfficerAug 14 '26Buy15.0020,000300,000121,248Aug 17 07:32 PM
LIN PETER KUAN-HOWChief Financial OfficerAug 14 '26Buy15.0026,667400,00548,979Aug 17 07:23 PM
Chen Hung-WenChief Executive OfficerAug 14 '26Buy15.00266,6674,000,0051,029,695Aug 17 07:13 PM
Chen Hung-WenChief Executive OfficerAug 14 '26Buy13.15270,0003,549,999418,334Aug 17 07:13 PM
LIN PETER KUAN-HOWChief Financial OfficerJun 15 '26Option Exercise0.0010,000025,900Jun 17 07:31 PM
Chen Hung-WenChief Executive OfficerJun 15 '26Option Exercise0.005,0000148,334Jun 16 05:11 PM
CHU YI-ANDirectorJun 15 '26Option Exercise0.0050001,500Jun 16 05:09 PM

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2024Q12024-05-29-17.000-17.000---1
2023S22024-03-28-24.000--24.478---
2023S12023-09-28-255--255.41---
2023Q22023-08-30-16.000-16.000---1
2023Q12023-05-31-16.000-----

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-60.500--61.5974.30-
2023FY-232--231.964.80-
2024FY-52.800--1934.80-
2025FY--92.000-7.565-1.00
2026FY--122--0.00
2027FY--138--0.00
2028FY--138--12.80

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2025FYS2024-09-121001.001.001.00
2025FYS2024-09-111001.001.001.00
2025FYS2024-09-101001.001.001.00
2025FYS2024-09-091001.001.001.00
2025FYS2024-09-081001.001.001.00
2025FYS2024-09-071001.001.001.00
2025FYS2024-09-061001.001.001.00
2025FYS2024-09-051001.001.001.00
2025FYS2024-09-041001.001.001.00
2025FYS2024-09-031001.001.001.00
2025FYS2024-09-021001.001.001.00
2025FYS2024-09-011001.001.001.00
2025FYS2024-08-311001.001.001.00
2025FYS2024-08-301001.001.001.00

Estimate history

EPS, annual-15.048-20.698-23.454-61.597-231.956-52.802-7.565
Period2019202020212022202320242025
EPS, quarterly-2.651-1.765
PeriodQ1 '22Q2 '22
Sales, annual0000008.5
Period2019202020212022202320242025
Sales, quarterly00
PeriodQ1 '22Q2 '22
Shares, annual3.2023.6043.7923.9490.8951.1032.147
Period2019202020212022202320242025
Shares, quarterly0.1340.134
PeriodQ1 '22Q2 '22

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.008.500.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.260.360.690.780.680.610.37
Gross Profit0.008.24-0.36-0.69-0.78-0.68-0.61-0.37
Selling, General and Administrative Excl. Other9.6517.7241.9754.1444.6350.1841.8824.38
Research and Development2.885.5324.5734.1935.4635.5731.4418.44
Other Operating Expense-0.000.000.000.000.000.000.00
Operating Income--9.47-42.33-54.83-45.40-50.86-42.48-24.75
Interest Expense0.160.070.180.150.090.080.070.05
Unusual Expense-0.081.7412.5874.01189.3240.4227.4622.21
Net Income Before Taxes-7.22-10.94-53.60-172.59-240.81-94.80-74.91-45.75
Income Taxes0.000.000.260.010.000.00-0.090.15
Consolidated Net Income-7.22-10.94-53.86-172.60-240.81-94.80-74.82-45.91
Net Income From Continuing Operations-7.22-10.94-53.86-172.60-240.81-94.80-74.82-45.91
Net Income-7.22-10.94-53.86-172.60-240.81-94.80-74.82-45.91
EPS (Recurring)-3.35-6.72-44.17-162.33-27.70-16.45-15.38-9.95
EPS (Basic, Before Extraordinaries)-0.26-7.57-52.80-231.96-61.60-23.45-20.70-15.05
EPS (Diluted)-0.26-7.57-52.80-231.96-61.60-23.45-20.70-15.05
EBITDA--9.22-41.97-54.14-44.63-50.18-41.88-24.38
Non-Operating Income (Expense)0.460.341.49-43.59-5.99-3.43-4.881.25
Other After Tax Adjustments-0.000.000.000.000.000.000.00
Stock Option Compensation Expense--0.738.199.512.696.093.380.08
Price To Sales Ratio-3.18------
Gross Margin-97.00------
Operating Margin--111.45------
Net Margin--128.69------
Shares Outstanding-2.151.100.893.953.793.603.20
Market Capitalization54.2254.2210.756.19139.11133.34133.34-

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S1
Total Revenue0.000.008.500.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.00-0.160.200.340.36
Gross Profit0.000.00--0.16-0.20-0.34-0.36
Selling, General and Administrative Excl. Other8.740.9119.1115.0926.8828.3325.81
Research and Development1.970.914.627.6416.9317.6816.52
Other Operating Expense0.00--0.000.000.000.00
Operating Income-8.74--10.61-15.26-27.08-28.66-26.17
Interest Expense0.130.030.040.050.130.090.06
Unusual Expense0.06-0.151.882.949.64-1.2875.29
Net Income Before Taxes-8.821.60-12.54-18.39-35.21-21.91-150.68
Income Taxes0.000.000.000.260.000.000.01
Consolidated Net Income-8.821.60-12.54-18.65-35.21-21.91-150.69
Net Income From Continuing Operations-8.821.60-12.54-18.65-35.21-21.91-150.69
Net Income-8.821.60-12.54-18.65-35.21-21.91-150.69
EPS (Recurring)-4.04--10.17-15.05-30.36-25.48-166.08
EPS (Basic, Before Extraordinaries)-4.063.80-11.37-16.91-37.56-24.48-255.41
EPS (Diluted)-4.063.80-11.37-16.91-37.56-24.48-255.41
EBITDA----15.09-26.88-28.33-25.81
Non-Operating Income (Expense)0.110.35-0.01-0.151.655.57-49.16
Stock Option Compensation Expense---2.036.175.553.96
Price To Sales Ratio--0.85----
Operating Margin---124.80----
Net Margin---147.48----
Shares Outstanding---1.101.100.890.06
Market Capitalization54.2220.637.2410.7518.876.1936.74

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments3.289.7737.8254.6194.48154.3974.12
Short Term Receivables2.490.130.470.550.510.410.36
Inventories0.000.000.000.000.000.000.00
Other Current Assets0.280.371.640.632.121.910.95
Total Current Assets6.0510.2739.9255.7997.11156.7175.43
Net Property, Plant & Equipment0.581.020.591.481.321.872.01
Total Investments and Advances0.000.000.004.317.840.000.00
Intangible Assets0.001.7414.7614.7814.8010.321.34
Deferred Tax Assets------0.18
Other Assets0.080.070.120.122.371.040.10
Total Assets6.7113.1055.3976.47123.44169.9479.05
Short Term Debt Incl. Current Port. of LT Debt0.210.234.390.682.153.760.77
Accounts Payable0.000.000.000.000.000.000.00
Income Tax Payable----0.000.150.15
Other Current Liabilities6.127.179.1611.6811.408.173.66
Total Current Liabilities6.337.4013.5612.3613.5612.084.58
Long Term Debt0.430.730.27512.24322.74285.79135.20
Provision for Risks Charges0.120.100.330.000.000.000.00
Other Liabilities3.020.000.000.000.000.000.00
Total Liabilities9.908.2314.15524.60336.30297.87139.78
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity-3.194.8641.23-448.12-212.86-127.93-60.72
Total Shareholders Equity-3.194.8641.23-448.12-212.86-127.93-60.72
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity-3.194.8641.23-448.12-212.86-127.93-60.72
Total Liabilities & Stockholders Equity6.7113.1055.3976.47123.44169.9479.05
Book Value Per Share-1.484.4146.07-113.48-56.14-35.50-18.96
Tangible Book Value Per Share-1.482.8429.58-117.23-60.04-38.36-19.38
Full-Time Employees1413454359--
Price to Book Ratio4.2251.530.11-34.01-46.056,954.76-
Return on Assets-110.43-157.28-261.79-240.92-64.62-60.10-
Return on Equity-1,305.37-233.67-----
Return on Invested Capital--962.27-415.90-375.57-86.27-47.40-61.64
Quick Ratio0.961.392.954.517.1612.9716.48
Current Ratio0.961.392.954.517.1612.9716.48

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income--10.94-53.60-172.59-240.81-94.80-74.91-45.75
Depreciation-0.260.360.670.780.680.610.37
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00
Other Funds (Non Cash)-0.7823.46132.98191.0648.5435.8122.33
Funds from Operations--9.90-29.78-38.94-48.97-45.57-38.48-23.05
Extraordinary Item-0.000.000.000.000.000.000.00
Changes in Working Capital--0.381.04-3.576.492.643.061.11
Cash from Operating Activities--10.28-28.74-42.51-42.49-42.93-35.42-21.94
Capital Expenditures-0.00-0.02-0.01-0.37-7.55-10.14-0.86
Net Assets From Acquisitions-0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.050.000.060.000.000.000.00
Purchase or Sale of Investments-0.005.7620.4929.00-31.8412.00-29.00
Purchase of Investments-0.000.000.000.00-103.79-6.00-89.40
Sale Or Maturity of Investments-0.005.7620.4929.0071.9518.0060.40
Other Uses-0.000.000.00-0.02-0.030.00-0.01
Other Sources-0.020.040.010.010.000.140.00
Cash from Investing Activities-0.075.7920.5428.62-39.422.00-29.86
Cash Dividends Paid-0.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Change in Capital Stock-3.875.0517.560.39-1.03126.069.82
Repurchase of Common Pref Stock-0.000.000.000.000.000.000.00
Sale of Common Pref Stock-3.875.0517.560.39-1.03126.069.82
Proceedsfrom Stock Options-3.865.0517.470.00-1.17120.039.82
Issuance or Reduction of Debt, Net-0.00-4.224.240.000.000.000.00
Change in Long Term Debt-0.000.000.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.000.000.000.000.000.00
Other Financing Activities Uses-0.000.000.000.000.000.000.00
Cash from Financing Activities-3.740.6621.35-0.20-1.56125.599.51
Exchange Rate Effect--0.020.00-----
Net Change in Cash--6.49-22.29-0.62-14.07-83.9192.16-42.29
Free Cash Flow--10.28-28.76-42.52-42.85-42.98-35.57-22.30

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments1.013.282.099.7725.9337.82
Short Term Receivables0.002.317.200.130.350.47
Inventories---0.000.000.00
Other Current Assets0.640.470.830.372.131.64
Total Current Assets1.656.0510.1310.2728.4139.92
Net Property, Plant & Equipment0.490.580.681.021.300.59
Total Investments and Advances---0.000.000.00
Intangible Assets-0.000.231.744.7514.76
Other Assets0.080.080.080.070.110.12
Total Assets2.216.7111.1213.1034.5755.39
Short Term Debt Incl. Current Port. of LT Debt1.500.210.200.233.774.39
Accounts Payable---0.000.000.00
Other Current Liabilities9.436.1210.277.178.889.16
Total Current Liabilities10.936.3310.477.4012.6513.56
Long Term Debt0.360.430.540.730.950.27
Other Liabilities1.523.024.020.000.000.00
Total Liabilities13.049.9015.528.2313.7714.15
Non-Equity Reserves---0.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-10.82-3.19-4.404.8620.8141.23
Total Shareholders Equity-10.82-3.19-4.404.8620.8141.23
Accumulated Minority Interest---0.000.000.00
Total Equity-10.82-3.19-4.404.8620.8141.23
Total Liabilities & Stockholders Equity2.216.7111.1213.1034.5755.39
Book Value Per Share---4.4118.9246.07
Tangible Book Value Per Share---2.8414.6029.58
Price to Book Ratio4.224.241.4951.530.460.11
Return on Assets-108.32-110.43-136.51-157.28-107.81-
Return on Equity--1,305.37-380.13-233.67-149.31-
Return on Invested Capital----333.25-161.81-52.79
Quick Ratio---1.392.252.95
Current Ratio0.150.960.971.392.252.95

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Net Income----18.39-35.21-21.91
Depreciation---0.160.200.31
Other Funds (Non Cash)---5.5217.944.79
Funds from Operations----12.71-17.07-16.81
Extraordinary Item---0.000.000.00
Changes in Working Capital---0.090.94-1.68
Cash from Operating Activities----12.62-16.12-18.49
Capital Expenditures----0.00-0.02-0.00
Net Assets From Acquisitions---0.000.000.00
Sale of Fixed Assets and Businesses---0.000.000.06
Purchase or Sale of Investments---0.005.7621.10
Purchase of Investments---0.000.004.92
Sale Or Maturity of Investments---0.005.7616.18
Other Uses---0.000.000.00
Other Sources---0.040.011E-15
Cash from Investing Activities---0.045.7521.16
Cash Dividends Paid---0.000.000.00
Preferred Dividends (Cash Flow)---0.000.000.00
Change in Capital Stock---0.005.050.00
Repurchase of Common Pref Stock---0.000.000.00
Sale of Common Pref Stock---0.005.050.00
Proceedsfrom Stock Options---0.005.050.00
Issuance or Reduction of Debt, Net----3.51-0.714.24
Change in Long Term Debt---0.000.000.00
Issuance of Long Term Debt---0.000.000.00
Reduction of Long Term Debt---0.000.000.00
Net Financing Active Other Cash Flow---0.000.000.00
Other Financing Activities Uses---0.000.000.00
Cash from Financing Activities----3.594.254.11
Exchange Rate Effect---0.01-0.01-
Net Change in Cash----16.16-6.136.76
Free Cash Flow----12.62-16.15-18.49

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.44%0.0M1.2M19.15K
2026-10-150.44%0.0M1.2M17.41K
2026-09-300.83%0.0M0.7M22.82K
2026-09-150.82%0.0M0.7M25.04K
2026-08-311.37%0.0M0.5M24.44K
2026-08-141.13%0.0M0.5M25.41K
2026-07-310.60%0.0M1.1M17.77K
2026-07-150.90%0.0M1.1M16.15K
2026-06-300.46%0.0M1.1M11.57K
2026-06-150.22%0.0M1.1M8.44K
2026-05-290.14%0.0M1.2M7.93K
2026-05-150.30%0.0M1.1M7.53K
2026-04-300.28%0.0M1.0M9.10K
2026-04-151.27%0.0M0.5M10.93K
2026-03-31-0.0M-11.44K
2026-03-13-0.0M-16.54K
2026-02-27-0.0M-22.52K
2026-02-13-0.0M-24.87K
2026-01-30-0.0M-35.48K
2026-01-15-0.0M-43.79K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-244/A2026-09-14SEC
2026-09-244/A2026-09-14SEC
2026-09-244/A2026-09-14SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-08424B3SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-19DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-17SCHEDULE 13D/ASEC
2026-08-14SCHEDULE 13D/ASEC
2026-08-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-11SEC
2026-07-243Initial statement of beneficial ownership of securities2026-07-20SEC
2026-07-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-21SEC
2026-07-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-14SEC
2026-06-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-24SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-164Statement of changes in beneficial ownership of securities2026-06-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-088.25M400
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
CITADEL ADVISORS LLC0.49%
SBI Securities Co., Ltd.0.00%
UBS Group AG0.00%
BlackRock, Inc.0.00%
CITIGROUP INC0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.07%

OakChart. APLM. Cached 15 minutes.

Some panels did not load: ratings, news.